Clinical Trials Logo

Major Depressive Disorder clinical trials

View clinical trials related to Major Depressive Disorder.

Filter by:

NCT ID: NCT00277823 Completed - Clinical trials for Major Depressive Disorder

Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder

Start date: February 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo.

NCT ID: NCT00265291 Completed - Clinical trials for Major Depressive Disorder

Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group

Start date: November 1999
Phase: Phase 2
Study type: Interventional

Our goal is to study pharmacogenetics in Mexican-Americans, using depression treatments as a proof of the concept that pharmacogenetic approaches can be used to optimize treatment strategies for common and complex disorders in this population.

NCT ID: NCT00252356 Completed - Clinical trials for Major Depressive Disorder

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder

ORION
Start date: September 2005
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy of a fixed dose of SR58611A(350 mg q12) compared to placebo in patients with MajorDepressive Disorder (MDD) using escitalopram (10 mgqd) as positive control. The study is a multicenter, US and Canadian, randomized, double-blind, 3-parallel-group, placebo- and escitalopram-controlled, Phase III study consisting of four segments (A, B, C and D). Segment A is a 1-week, placebo, single-blind period. Segment B is an 8-week, double-blind period. Segment C is an optional 18-week double-blind extension period. Segment D is a 1-week safety follow-up period after study drug discontinuation or early termination (during Segment B or C).

NCT ID: NCT00252330 Completed - Clinical trials for Major Depressive Disorder

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder

PHOENIX
Start date: September 2005
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy of a fixed dose of SR58611A(350 mg q12) compared to placebo in patients with MajorDepressive Disorder (MDD) using escitalopram (10 mgqd) as positive control. In addition, the tolerability and safety of SR58611A in patients with MDD will be evaluated.

NCT ID: NCT00245557 Completed - Clinical trials for Major Depressive Disorder

Magnetic Resonance Imaging Study of Geriatric Depression

Start date: November 2004
Phase: N/A
Study type: Interventional

The purpose of this study was to use Magnetic Resonance Images to further our understanding of predictors and markers of treatment response and non-response in geriatric depression. We hypothesized that concentrations of high energy metabolites would be lower in depressed elderly compared to non-depressed.

NCT ID: NCT00242229 Completed - Clinical trials for Major Depressive Disorder

Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder

Start date: October 2004
Phase: N/A
Study type: Interventional

To evaluate the overall safety and tolerability profile of two dose levels of DVS-233 SR during 6 months of open-label treatment in elderly outpatients with major depressive disorder.

NCT ID: NCT00234195 Completed - Breast Cancer Clinical Trials

Wellbutrin XL, Major Depressive Disorder and Breast Cancer

Start date: September 2005
Phase: Phase 4
Study type: Interventional

- To evaluate the efficacy of bupropion extended release (Wellbutrin XL™) in the treatment of Major Depressive Disorder in women with breast cancer. - To evaluate the tolerability of bupropion extended-release (Wellbutrin XL™) in these patients

NCT ID: NCT00232700 Completed - Clinical trials for Major Depressive Disorder

Investigation of a Combination Treatment of Escitalopram and rTMS

Start date: September 2005
Phase: N/A
Study type: Interventional

We intend to test in a randomized, rater blinded, placebo controlled, prospective study the primary hypothesis that an escitalopram-rTMS-combination treatment is more efficacious in the treatment of refractory major depression assessed with the Hamilton Depression Rating Scale

NCT ID: NCT00229398 Completed - Clinical trials for Major Depressive Disorder

Medical and Psychiatric Co-Morbidity Among Treatment Resistant Patients With Major Depression Disorder

Start date: November 1998
Phase: N/A
Study type: Observational

Assessing psychiatric and physiological co-morbidity in TRD and non-TRD patients

NCT ID: NCT00229294 Completed - Clinical trials for Major Depressive Disorder

Fibromyalgia in Men Suffering From PTSD

Start date: March 2004
Phase: N/A
Study type: Observational

Assessing FM and psychiatric state among PTSD, MDD and healthy participants